Pedersen, M. A., Dias, A. H., Hjorthaug, K., Gormsen, L. C., Fledelius, J., Johnsson, A. L.
, Borgquist, S., Tramm, T., Munk, O. L. & Vendelbo, M. H. (2024).
Increased lesion detectability in patients with locally advanced breast cancer-A pilot study using dynamic whole-body [
18F]FDG PET/CT. EJNMMI research,
14(1), 31. Article 31.
https://doi.org/10.1186/s13550-024-01096-4
Pedersen, M. A., Gormsen, L. C., Jakobsen, L. H., Eyre, T. A.
, Severinsen, M. T., Baech, J., Dann, E. J., Knapp, A., Sahin, D.
, Vestergaard, P., El-Galaly, T. C. & Jensen, P. (2024).
The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
British Journal of Haematology,
204(4), 1271-1278.
https://doi.org/10.1111/bjh.19194
Stochholm, K., Holmgård, C., Davis, S. M.
, Gravholt, C. H. & Berglund, A. (2024).
Incidence, prevalence, age at diagnosis, and mortality in individuals with 45,X/46,XY mosaicism: a population-based registry study.
Genetics in medicine : official journal of the American College of Medical Genetics,
26(1), Article 100987.
https://doi.org/10.1016/j.gim.2023.100987
Tarai, S., Lundström, E., Sjöholm, T., Jönsson, H., Korenyushkin, A., Ahmad, N.
, Pedersen, M. A., Molin, D., Enblad, G., Strand, R., Ahlström, H. & Kullberg, J. (2024).
Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors.
Heliyon,
10(4), Article e26414.
https://doi.org/10.1016/j.heliyon.2024.e26414
Torbjørnsen, A., Spildo, I., Mollestad, M. A.
, Jensen, A. L., Singstad, T., Weldingh, N. M., Joranger, P., Ribu, L. & Holmen, H. (2024).
Investigating Digital Patient-Reported Outcome Measures in Patient-Centered Diabetes Specialist Outpatient Care (DigiDiaS): Protocol for a Multimethod Prospective Observational Study.
JMIR Research Protocols,
13(1), Article e52766.
https://doi.org/10.2196/52766
Vernstrøm, L., Gullaksen, S., Sørensen, S. S., Funck, K. L., Laugesen, E. & Poulsen, P. L. (2024).
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
Diabetes, Obesity and Metabolism,
26(5), 1624-1635.
https://doi.org/10.1111/dom.15464
Villumsen, B., Frystyk, J., Jørgensen, M. G., Hørdam, B.
& Borre, M. (2024).
Exergaming Improves Cardiac Risk Factors in Prostate Cancer Patients: A Single-Blinded Randomized Controlled Trial.
Games for Health,
13(1), 93-99.
https://doi.org/10.1089/g4h.2023.0096
Voigt, J. H., Lauritsen, K. M.
, Pedersen, S. B., Hansen, T. K., Møller, N., Jessen, N., Laurenti, M. C., Dalla Man, C., Vella, A.
, Gormsen, L. C. & Søndergaard, E. (2024).
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes.
Basic & Clinical Pharmacology & Toxicology,
134(5).
https://doi.org/10.1111/bcpt.13991
Wang, Q. J., Costa Correa, C. M., Andersen, S. K., Birkle, P.
& Jeppesen, P. B. (2024).
Metabolic effects of colour- and odour-induced sweetness enhancement.
Food Quality and Preference,
113, Article 105056.
https://doi.org/10.1016/j.foodqual.2023.105056
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R.
, Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J. & Drucker, D. J. (2024).
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.
Cell Metabolism,
36(1), 130-143.e5.
https://doi.org/10.1016/j.cmet.2023.11.009